Roche's Gazyva Cancer Drug Outperforms MabThera
15 June 2018 - 5:20PM
Dow Jones News
By Nathan Allen
Roche Holding AG (RO.EB) said Friday that long-term data confirm
its Gazyva cancer drug extends the lives of people with a chronic
form of leukemia compared with its MabThera treatment.
After a follow-up period of five years, data from the final
analysis of Roche's CLL11 study show a 51% reduction in the risk of
disease progression or death in patients treated with Gazyva,
compared with patients treated with its MabThera medication, the
company said.
Gazyva is approved for use in combination with chlorambucil in
more than 90 countries, Roche said.
Write to Nathan Allen at nathan.allen@dowjones.com
(END) Dow Jones Newswires
June 15, 2018 03:05 ET (07:05 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024